# Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

> **NCT04128800** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Apatinib S-1

## Key facts

- **NCT ID:** NCT04128800
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04128800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04128800, "Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT04128800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*